
## Jae-Ho Cheong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3210865/publications.pdf Version: 2024-02-01



INF-HO CHEONC

#	Article	lF	CITATIONS
1	Radiological criteria for selecting candidates for neoadjuvant chemotherapy for gastric cancer: an exploratory analysis from the PRODIGY study. Gastric Cancer, 2022, 25, 170-179.	5.3	6
2	Two distinct stem cellâ€like subtypes of hepatocellular carcinoma with clinical significance and their therapeutic potentials. Cancer Communications, 2022, 42, 179-183.	9.2	3
3	Development and validation of a prognostic and predictive 32-gene signature for gastric cancer. Nature Communications, 2022, 13, 774.	12.8	52
4	New Immunometabolic Strategy Based on Cell Type-Specific Metabolic Reprogramming in the Tumor Immune Microenvironment. Cells, 2022, 11, 768.	4.1	14
5	The Matrisome Is Associated with Metabolic Reprograming in Stem-like Phenotypes of Gastric Cancer. Cancers, 2022, 14, 1438.	3.7	8
6	1H NMR based urinary metabolites profiling dataset of canine mammary tumors. Scientific Data, 2022, 9, 132.	5.3	3
7	Intercellular communications and metabolic reprogramming as new predictive markers for immunotherapy responses in gastric cancer. Cancer Communications, 2022, 42, 572-575.	9.2	7
8	Clinicopathologic and genomic characteristics of mucinous gastric adenocarcinoma. Gastric Cancer, 2022, 25, 697-711.	5.3	7
9	Synaptotagmin 11 scaffolds MKK7–JNK signaling process to promote stem-like molecular subtype gastric cancer oncogenesis. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	8.6	7
10	Machine Learning Predictor of Immune Checkpoint Blockade Response in Gastric Cancer. Cancers, 2022, 14, 3191.	3.7	8
11	First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. Investigational New Drugs, 2022, 40, 1001-1010.	2.6	14
12	SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence. Gastric Cancer, 2021, 24, 589-601.	5.3	12
13	Matrix stiffness epigenetically regulates the oncogenic activation of the Yes-associated protein in gastric cancer. Nature Biomedical Engineering, 2021, 5, 114-123.	22.5	65
14	Functional inhibition of fatty acid binding protein 4 ameliorates impaired ciliogenesis in GCs. Biochemical and Biophysical Research Communications, 2021, 539, 28-33.	2.1	3
15	Prognostic Value of Postoperative Neutrophil and Albumin: Reassessment One Month After Gastric Cancer Surgery. Frontiers in Oncology, 2021, 11, 633924.	2.8	7
16	Perioperative, short-, and long-term outcomes of gastric cancer surgery: Propensity score-matched analysis of patients with or without prior solid organ transplantation. European Journal of Surgical Oncology, 2021, 47, 3105-3112.	1.0	1
17	Pan-Cancer Analysis Reveals Distinct Metabolic Reprogramming in Different Epithelial–Mesenchymal Transition Activity States. Cancers, 2021, 13, 1778.	3.7	10
18	Sp1-Induced FNBP1 Drives Rigorous 3D Cell Motility in EMT-Type Gastric Cancer Cells. International Journal of Molecular Sciences, 2021, 22, 6784.	4.1	5

#	Article	IF	CITATIONS
19	Long nonâ€coding RNAs are significantly associated with prognosis and response to therapies in gastric cancer. Clinical and Translational Medicine, 2021, 11, e421.	4.0	2
20	Long-chain polyphosphates impair SARS-CoV-2 infection and replication. Science Signaling, 2021, 14, .	3.6	27
21	Prevalence of cancer susceptibility variants in patients with multiple Lynch syndrome related cancers. Scientific Reports, 2021, 11, 14807.	3.3	8
22	Microsatellite Instability and Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer: A Multicohort Study. Annals of Surgical Oncology, 2021, 28, 8908-8915.	1.5	4
23	Alternative lengthening of telomeres is mechanistically linked to potential therapeutic vulnerability in the stemâ€ike subtype of gastric cancer. Clinical and Translational Medicine, 2021, 11, e561.	4.0	6
24	ASO Video Abstract: Microsatellite Instability and the Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer—A Multi-cohort Study. Annals of Surgical Oncology, 2021, 28, 688.	1.5	0
25	CDX-1/CDX-2 Expression Is a Favorable Prognostic Factor in Epstein-Barr Virus-Negative, Mismatch Repair-Proficient Advanced Gastric Cancers. Gut and Liver, 2021, 15, 694-704.	2.9	0
26	Development and validation of deep learning classifiers to detect Epstein-Barr virus and microsatellite instability status in gastric cancer: a retrospective multicentre cohort study. The Lancet Digital Health, 2021, 3, e654-e664.	12.3	69
27	Pan-Cancer Analysis of Clinical Relevance via Telomere Maintenance Mechanism. International Journal of Molecular Sciences, 2021, 22, 11101.	4.1	5
28	Single patient classifier as a prognostic biomarker in pT1N1 gastric cancer: Results from two large Korean cohorts. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 583-591.	2.2	2
29	Prognostic significance of body mass index and prognostic nutritional index in stage II/III gastric cancer. European Journal of Surgical Oncology, 2020, 46, 620-625.	1.0	43
30	Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer. Molecular Therapy - Oncolytics, 2020, 18, 587-601.	4.4	38
31	Cross-species oncogenic signatures of breast cancer in canine mammary tumors. Nature Communications, 2020, 11, 3616.	12.8	58
32	Role of Mitochondria-Cytoskeleton Interactions in the Regulation of Mitochondrial Structure and Function in Cancer Stem Cells. Cells, 2020, 9, 1691.	4.1	20
33	FoxM1-dependent and fatty acid oxidation-mediated ROS modulation is a cell-intrinsic drug resistance mechanism in cancer stem-like cells. Redox Biology, 2020, 36, 101589.	9.0	55
34	Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors Journal of Clinical Oncology, 2020, 38, 3590-3590.	1.6	12
35	A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer. Cancer Research and Treatment, 2020, 52, 1153-1161.	3.0	9
36	Contrasting Prognostic Effects of Tumor-Infiltrating Lymphocyte Density in Cardia and Non-cardia Gastric Adenocarcinomas. Journal of Gastric Cancer, 2020, 20, 190.	2.5	1

#	Article	IF	CITATIONS
37	Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer. Annals of Surgery, 2019, 270, 309-316.	4.2	191
38	VEGF-C induced by TGF- β1 signaling in gastric cancer enhances tumor-induced lymphangiogenesis. BMC Cancer, 2019, 19, 799.	2.6	32
39	Whole-exome and whole-transcriptome sequencing of canine mammary gland tumors. Scientific Data, 2019, 6, 147.	5.3	24
40	Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer. Radiotherapy and Oncology, 2019, 140, 143-149.	0.6	7
41	Multiâ€institutional validation of the 8th AJCC TNM staging system for gastric cancer: Analysis of survival data from highâ€volume Eastern centers and the SEER database. Journal of Surgical Oncology, 2019, 120, 676-684.	1.7	35
42	Gastric cancer depends on aldehyde dehydrogenase 3A1 for fatty acid oxidation. Scientific Reports, 2019, 9, 16313.	3.3	27
43	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. Journal of Clinical Oncology, 2019, 37, 3392-3400.	1.6	293
44	Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial. Yonsei Medical Journal, 2019, 60, 132.	2.2	31
45	The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer. Molecular Cancer Therapeutics, 2019, 18, 1439-1450.	4.1	12
46	Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer. Gastric Cancer, 2019, 22, 1153-1163.	5.3	19
47	Comment on "To Treat, or Not to Treat, That is the Question Biomarker-guided Adjuvant Chemotherapy for Stage II and III Gastric Cancerâ€: Annals of Surgery, 2019, 270, e40-e41.	4.2	6
48	S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. Cancer Research and Treatment, 2019, 51, 1-11.	3.0	17
49	A Therapeutic Strategy for Chemotherapy-Resistant Gastric Cancer via Destabilization of Both β-Catenin and RAS. Cancers, 2019, 11, 496.	3.7	9
50	Mitochondria-centric bioenergetic characteristics in cancer stem-like cells. Archives of Pharmacal Research, 2019, 42, 113-127.	6.3	47
51	Ten Thousand Consecutive Gastrectomies for Gastric Cancer: Perspectives of a Master Surgeon. Yonsei Medical Journal, 2019, 60, 235.	2.2	11
52	EPB41L5 Mediates TGFÎ <sup>2</sup> -Induced Metastasis of Gastric Cancer. Clinical Cancer Research, 2019, 25, 3617-3629.	7.0	27
53	Clinical Implementation of Precision Medicine in Gastric Cancer. Journal of Gastric Cancer, 2019, 19, 235.	2.5	16
54	Mismatch Repair Status of Gastric Cancer and Its Association with the Local and Systemic Immune Response. Oncologist, 2019, 24, e835-e844.	3.7	14

#	Article	IF	CITATIONS
55	Extracellular vesicle (EV)-polyphenol nanoaggregates for microRNA-based cancer diagnosis. NPG Asia Materials, 2019, 11, .	7.9	10
56	The optimal timing of additional surgery after non-curative endoscopic resection to treat early gastric cancer: long-term follow-up study. Scientific Reports, 2019, 9, 18331.	3.3	7
57	Prognostic Impact of Extended Lymph Node Dissection versus Limited Lymph Node Dissection on pN0 Proximal Advanced Gastric Cancer: a Propensity Score Matching Analysis. Journal of Gastric Cancer, 2019, 19, 212.	2.5	5
58	PI3K/AKT/β-Catenin Signaling Regulates Vestigial-Like 1 Which Predicts Poor Prognosis and Enhances Malignant Phenotype in Gastric Cancer. Cancers, 2019, 11, 1923.	3.7	22
59	A case of gastric cancer metastasis to the breast in a female with BRCA2 germline mutation and literature review. Acta Chirurgica Belgica, 2019, 119, 59-63.	0.4	10
60	MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs) Journal of Clinical Oncology, 2019, 37, 66-66.	1.6	17
61	Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial. Cancer Research and Treatment, 2019, 51, 819-831.	3.0	10
62	Clinical Implications of Microsatellite Instability in Early Gastric Cancer. Journal of Gastric Cancer, 2019, 19, 427.	2.5	15
63	Rab25 augments cancer cell invasiveness through a β1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin. Experimental and Molecular Medicine, 2018, 50, e435-e435.	7.7	45
64	Survival of Cancer Stem-Like Cells Under Metabolic Stress via CaMK2α-mediated Upregulation of Sarco/Endoplasmic Reticulum Calcium ATPase Expression. Clinical Cancer Research, 2018, 24, 1677-1690.	7.0	29
65	Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nature Communications, 2018, 9, 1777.	12.8	245
66	Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis. Lancet Oncology, The, 2018, 19, 629-638.	10.7	172
67	Comparative study between endoscopic submucosal dissection and surgery in patients with early gastric cancer. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 73-86.	2.4	84
68	Long-term outcomes of endoscopic submucosal dissection in comparison to surgery in undifferentiated-type intramucosal gastric cancer using propensity score analysis. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 2046-2057.	2.4	32
69	Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy. BMC Cancer, 2018, 18, 1116.	2.6	51
70	Inhibition of Wntless/GPR177 suppresses gastric tumorigenesis. BMB Reports, 2018, 51, 255-260.	2.4	11
71	Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer. Nature Communications, 2018, 9, 1920.	12.8	85
72	Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT. Gastroenterology, 2018, 155, 799-814.e13.	1.3	83

#	Article	IF	CITATIONS
73	Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial. Annals of Surgical Oncology, 2018, 25, 3222-3230.	1.5	69
74	Parameters for Predicting Surgical Outcomes for Gastric Cancer Patients: Simple Is Better Than Complex. Annals of Surgical Oncology, 2018, 25, 3239-3247.	1.5	55
75	Modification of the TNM Staging System for Stage II/III Gastric Cancer Based on a Prognostic Single Patient Classifier Algorithm. Journal of Gastric Cancer, 2018, 18, 142.	2.5	12
76	Increased extracellular matrix density disrupts E-cadherin/β-catenin complex in gastric cancer cells. Biomaterials Science, 2018, 6, 2704-2713.	5.4	47
77	Phase 1 study of an oxidative phosphorylation inhibitor IM156 in patients with advanced solid tumors Journal of Clinical Oncology, 2018, 36, TPS2620-TPS2620.	1.6	1
78	Validation of the 8th AJCC TNM staging system for gastric cancer: Survival analysis with high volume Asian centers and SEER database by comparing with 7th TNM staging system Journal of Clinical Oncology, 2018, 36, 18-18.	1.6	1
79	Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin. Neuro-Oncology, 2017, 19, now174.	1.2	43
80	Droplet-based microtumor model to assess cell-ECM interactions and drug resistance of gastric cancer cells. Scientific Reports, 2017, 7, 41541.	3.3	47
81	Snail reprograms glucose metabolism by repressing phosphofructokinase PFKP allowing cancer cell survival under metabolic stress. Nature Communications, 2017, 8, 14374.	12.8	144
82	Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. Clinical Cancer Research, 2017, 23, 4441-4449.	7.0	342
83	Distinct expression profile of key molecules in crawling-type early gastric carcinoma. Gastric Cancer, 2017, 20, 612-619.	5.3	7
84	Impact of splenic hilar lymph node metastasis on prognosis in patients with advanced gastric cancer. Oncotarget, 2017, 8, 84515-84528.	1.8	12
85	Clinical impact of microsatellite instability in patients with stage II and III gastric cancer: Results from the CLASSIC trial Journal of Clinical Oncology, 2017, 35, 4022-4022.	1.6	13
86	Superior prognosis prediction performance of deep learning for gastric cancer compared to Yonsei prognosis prediction model using Cox regression Journal of Clinical Oncology, 2017, 35, 164-164.	1.6	8
87	A proposal for a novel and simple TNM staging for gastric cancer Journal of Clinical Oncology, 2017, 35, 21-21.	1.6	1
88	Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. Oncotarget, 2017, 8, 38389-38398.	1.8	8
89	When Eastern Surgeons Meet Western Patients: A Pilot Study of Gastrectomy with Lymphadenectomy in Caucasian Patients at a Single Korean Institute. Yonsei Medical Journal, 2016, 57, 1294.	2.2	0
90	Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. Oncotarget, 2016, 7, 44608-44620.	1.8	46

#	Article	IF	CITATIONS
91	Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A). Oncotarget, 2016, 7, 65643-65659.	1.8	35
92	Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. Annals of Surgery, 2016, 263, 96-102.	4.2	56
93	Staging for Remnant Gastric Cancer: The Metastatic Lymph Node Ratio vs. the UICC 7th Edition System. Annals of Surgical Oncology, 2016, 23, 4322-4331.	1.5	32
94	Migration and invasion of drug-resistant lung adenocarcinoma cells are dependent on mitochondrial activity. Experimental and Molecular Medicine, 2016, 48, e277-e277.	7.7	49
95	Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. Clinical Cancer Research, 2016, 22, 6228-6235.	7.0	40
96	Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. Scientific Reports, 2016, 6, 22172.	3.3	90
97	Clinical Significance of the Prognostic Nutritional Index for Predicting Short- and Long-Term Surgical Outcomes After Gastrectomy. Medicine (United States), 2016, 95, e3539.	1.0	70
98	Differences in TGF-β1 signaling and clinicopathologic characteristics of histologic subtypes of gastric cancer. BMC Cancer, 2016, 16, 60.	2.6	14
99	Failure of a patient-derived xenograft for brain tumor model prepared by implantation of tissue fragments. Cancer Cell International, 2016, 16, 43.	4.1	17
100	An integrative somatic mutation analysis to identify pathways linked with survival outcomes across 19 cancer types. Bioinformatics, 2016, 32, 1643-1651.	4.1	35
101	Correlation analyses between pre- and post-operative adverse events in gastric cancer patients receiving preoperative treatment and gastrectomy. BMC Cancer, 2016, 16, 29.	2.6	1
102	Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer. Japanese Journal of Clinical Oncology, 2016, 46, 507-516.	1.3	11
103	Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. Annals of Nuclear Medicine, 2016, 30, 279-286.	2.2	16
104	Epstein–Barr virus positivity, not mismatch repair-deficiency, is a favorable risk factor for lymph node metastasis in submucosa-invasive early gastric cancer. Gastric Cancer, 2016, 19, 1041-1051.	5.3	43
105	Impact of the Surveillance Interval on the Survival of Patients Who Undergo Curative Surgery for Gastric Cancer. Annals of Surgical Oncology, 2016, 23, 539-545.	1.5	20
106	Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation. Gastric Cancer, 2016, 19, 951-960.	5.3	48
107	An update on the randomized phase III POST trial: S-1 based doublet as an adjuvant chemotherapy for curatively resected stage III gastric cancer Journal of Clinical Oncology, 2016, 34, 4042-4042.	1.6	1
108	A Lymph Node Staging System for Gastric Cancer: A Hybrid Type Based on Topographic and Numeric Systems. PLoS ONE, 2016, 11, e0149555.	2.5	24

#	Article	IF	CITATIONS
109	Periodic Endoscopies Might Not Increase the Detection of Early Gastric Cancer in a Young Population. PLoS ONE, 2016, 11, e0159759.	2.5	3
110	Integrated omics-analysis reveals Wnt-mediated NAD+ metabolic reprogramming in cancer stem-like cells. Oncotarget, 2016, 7, 48562-48576.	1.8	8
111	Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm. Oncotarget, 2016, 7, 72099-72112.	1.8	16
112	Strategies to improve treatment outcome in gastric cancer: A retrospective analysis of patients from two high-volume hospitals in Korea and China. Oncotarget, 2016, 7, 44660-44675.	1.8	21
113	Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives. Journal of Pathology and Translational Medicine, 2016, 50, 1-9.	1.1	21
114	A 30 gene panel as prognostic for survival outcomes in clinically resectable gastric cancer Journal of Clinical Oncology, 2016, 34, 4039-4039.	1.6	0
115	Difficulty of predicting the presence of lymph node metastases in patients with clinical early stage gastric cancer: a case control study. BMC Cancer, 2015, 15, 943.	2.6	22
116	The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses. International Journal of Cancer, 2015, 137, 819-825.	5.1	107
117	Oncologic Safety of Laparoscopic Wedge Resection with Gastrotomy for Gastric Gastrointestinal Stromal Tumor: Comparison with Conventional Laparoscopic Wedge Resection. Journal of Gastric Cancer, 2015, 15, 231.	2.5	9
118	Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine. Yonsei Medical Journal, 2015, 56, 1177.	2.2	49
119	Association between Chemotherapy-Response Assays and Subsets of Tumor-Infiltrating Lymphocytes in Gastric Cancer: A Pilot Study. Journal of Gastric Cancer, 2015, 15, 223.	2.5	11
120	Potential use of glioblastoma tumorsphere: clinical credentialing. Archives of Pharmacal Research, 2015, 38, 402-407.	6.3	23
121	Impact of carcinomatosis and ascites status on long-term outcomes of palliative treatment for patients with gastric outlet obstruction caused by unresectable gastric cancer: stent placement versus palliative gastrojejunostomy. Gastrointestinal Endoscopy, 2015, 81, 321-332.	1.0	45
122	Metabolism in embryonic and cancer stemness. Archives of Pharmacal Research, 2015, 38, 381-388.	6.3	37
123	Programmed cell death 5 mediates HDAC3 decay to promote genotoxic stress response. Nature Communications, 2015, 6, 7390.	12.8	40
124	Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer. Oncology, 2015, 88, 147-156.	1.9	15
125	Do All Patients Require Prophylactic Drainage After Gastrectomy for Gastric Cancer? The Experience of a High-Volume Center. Annals of Surgical Oncology, 2015, 22, 3929-3937.	1.5	20
126	The different role of intratumoral and peritumoral lymphangiogenesis in gastric cancer progression and prognosis. BMC Cancer, 2015, 15, 498.	2.6	21

#	Article	IF	CITATIONS
127	Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer. Annals of Surgical Oncology, 2015, 22, 224-231.	1.5	50
128	Celastrol inhibits gastric cancer growth by induction of apoptosis and autophagy. BMB Reports, 2014, 47, 697-702.	2.4	99
129	The optimal endoscopic screening interval for detecting early gastric neoplasms. Gastrointestinal Endoscopy, 2014, 80, 253-259.	1.0	24
130	Anatomic Extent of Metastatic Lymph Nodes: Still Important for Gastric Cancer Prognosis. Annals of Surgical Oncology, 2014, 21, 899-907.	1.5	20
131	Is microsatellite instability a prognostic marker in gastric cancer?: A systematic review with meta-analysis. Journal of Surgical Oncology, 2014, 110, 129-135.	1.7	106
132	Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 2014, 513, 202-209.	27.8	5,055
133	Minimally invasive surgery for remnant gastric cancer: a comparison with open surgery. Surgical Endoscopy and Other Interventional Techniques, 2014, 28, 2452-2458.	2.4	43
134	Long non-coding RNA HOTAIR promotes carcinogenesis and invasion of gastric adenocarcinoma. Biochemical and Biophysical Research Communications, 2014, 451, 171-178.	2.1	77
135	Tumor bioenergetics: An emerging avenue for cancer metabolism targeted therapy. BMB Reports, 2014, 47, 158-166.	2.4	27
136	Current practice of gastric cancer treatment. Chinese Medical Journal, 2014, 127, 547-53.	2.3	8
137	Prognostic Value of Early Postoperative Tumor Marker Response in Gastric Cancer. Annals of Surgical Oncology, 2013, 20, 3905-3911.	1.5	41
138	Staging of Adenocarcinoma of the Esophagogastric Junction: Comparison of AJCC 6th and 7th Gastric and 7th Esophageal Staging Systems. Annals of Surgical Oncology, 2013, 20, 2713-2720.	1.5	30
139	CD44-specific supramolecular hydrogels for fluorescence molecular imaging of stem-like gastric cancer cells. Integrative Biology (United Kingdom), 2013, 5, 669.	1.3	21
140	Hyaluronic acid receptor-targetable imidazolized nanovectors for induction of gastric cancer cell death by RNA interference. Biomaterials, 2013, 34, 4327-4338.	11.4	36
141	Signet ring cell mixed histology may show more aggressive behavior than other histologies in early gastric cancer. Journal of Surgical Oncology, 2013, 107, 124-129.	1.7	66
142	Advanced gastric cancer: is chemotherapy needed after surgery?. Expert Review of Gastroenterology and Hepatology, 2013, 7, 673-675.	3.0	4
143	Pathologic and Oncologic Outcomes in Locally Advanced Gastric Cancer with Neoadjuvant Chemotherapy or Chemoradiotherapy. Yonsei Medical Journal, 2013, 54, 888.	2.2	21
144	Functional Nanoplatforms for Enhancement of Chemotherapeutic Index. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 212-221.	1.7	3

#	Article	IF	CITATIONS
145	The effect of delay of adjuvant chemotherapy on survival in patients with resected stage II and III gastric cancer Journal of Clinical Oncology, 2013, 31, e15144-e15144.	1.6	0
146	Association of YAP1 activation with poor patient prognosis and effect on chemoresistance in gastric cancer Journal of Clinical Oncology, 2013, 31, 4113-4113.	1.6	0
147	Current Management and Future Strategies of Gastric Cancer. Yonsei Medical Journal, 2012, 53, 248.	2.2	57
148	Surgical Complications in Gastric Cancer Patients Preoperatively Treated with Chemotherapy: Their Risk Factors and Clinical Relevance. Annals of Surgical Oncology, 2012, 19, 2452-2458.	1.5	52
149	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
150	Safety and Efficacy of Fastâ€ŧrack Surgery in Laparoscopic Distal Gastrectomy for Gastric Cancer: A Randomized Clinical Trial. World Journal of Surgery, 2012, 36, 2879-2887.	1.6	122
151	Outcome after gastrectomy in gastric cancer patients with type 2 diabetes. World Journal of Gastroenterology, 2012, 18, 49.	3.3	61
152	Treatment Results of Small Intestinal Gastrointestinal Stromal Tumors Less than 10 cm in Diameter: A Comparison between Laparoscopy and Open Surgery. Journal of Gastric Cancer, 2012, 12, 243.	2.5	17
153	Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5â€FU based chemotherapy after R0 resection. International Journal of Cancer, 2012, 131, 505-511.	5.1	139
154	Clinical implication of an insufficient number of examined lymph nodes after curative resection for gastric cancer. Cancer, 2012, 118, 4687-4693.	4.1	88
155	AMPKα Modulation in Cancer Progression: Multilayer Integrative Analysis of the Whole Transcriptome in Asian Gastric Cancer. Cancer Research, 2012, 72, 2512-2521.	0.9	91
156	Long-term oncologic outcomes of 714 consecutive laparoscopic gastrectomies for gastric cancer: results from the 7-year experience of a single institute. Surgical Endoscopy and Other Interventional Techniques, 2012, 26, 130-136.	2.4	46
157	Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of primary gastric cancer Journal of Clinical Oncology, 2012, 30, e14504-e14504.	1.6	0
158	Comparison of S-1 and cisplatin combination versus S-1 adjuvant chemotherapy for advanced gastric cancer Journal of Clinical Oncology, 2012, 30, e14652-e14652.	1.6	0
159	Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer. Anticancer Research, 2012, 32, 3827-34.	1.1	51
160	Recent Evolution of Surgical Treatment for Gastric Cancer in Korea. Journal of Gastric Cancer, 2011, 11, 1.	2.5	24
161	Intracorporeal Anastomosis Using Linear Stapler in Laparoscopic Distal Gastrectomy: Comparison between Gastroduodenostomy and Gastrojejunostomy. Journal of Gastric Cancer, 2011, 11, 212.	2.5	15
162	Eupatilin Inhibits Gastric Cancer Cell Growth by Blocking STAT3-Mediated VEGF Expression. Journal of Gastric Cancer, 2011, 11, 16.	2.5	38

#	Article	IF	CITATIONS
163	Intraoperative portable abdominal radiograph for tumor localization: a simple and accurate method for laparoscopic gastrectomy. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 958-963.	2.4	75
164	Clinical implication of FDG–PET in advanced gastric cancer with signet ring cell histology. Journal of Surgical Oncology, 2011, 104, 566-570.	1.7	25
165	Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17456-17461.	7.1	116
166	Gene Expression Signature–Based Prognostic Risk Score in Gastric Cancer. Clinical Cancer Research, 2011, 17, 1850-1857.	7.0	285
167	Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models. Molecular Cancer Therapeutics, 2011, 10, 2350-2362.	4.1	219
168	Assessment of open versus laparoscopyâ€assisted gastrectomy in lymph nodeâ€positive early gastric cancer: A retrospective cohort analysis. Journal of Surgical Oncology, 2010, 102, 77-81.	1.7	59
169	Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness in the NCI 60 Cancer Cell Line Set. Molecular Cancer Therapeutics, 2010, 9, 257-267.	4.1	81
170	The impact of total retrieved lymph nodes on staging and survival of patients with pT3 gastric cancer. Cancer, 2007, 110, 745-751.	4.1	54
171	The N Ratio Predicts Recurrence and Poor Prognosis in Patients With Node-Positive Early Gastric Cancer. Annals of Surgical Oncology, 2006, 13, 377-385.	1.5	58
172	Early Postoperative Intraperitoneal Chemotherapy Following Cytoreductive Surgery in Patients with Very Advanced Gastric Cancer. Annals of Surgical Oncology, 2006, 14, 61-68.	1.5	33
173	Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer, 2005, 103, 2383-2390.	4.1	202
174	Minimally invasive treatment for gastric cancer: Approaches and selection process. Journal of Surgical Oncology, 2005, 90, 188-193.	1.7	48
175	Survival benefit of metastasectomy for Krukenberg tumors from gastric cancer. Gynecologic Oncology, 2004, 94, 477-482.	1.4	66